Chronic Kidney Disease: key endpoint results by drug
The key endpoints of Chronic Kidney Disease trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Chronic Kidney Disease page.
Kidney composite outcome
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Atrasentan | 6% | 7.9% | −1.9 | n 1325 | NCT01858532 Phase 3, primary |
| Dapagliflozin | 6.6% | 11.3% | −4.7 | n 2152 | NCT03036150 Phase 3, secondary |
| Empagliflozin | 6.1% | 8.1% | −2 | 10 mg · n 3304 | NCT03594110 Phase 3, secondary |
Drugs checked with no result here: 33 not reported, 21 trial running, 19 not posted.
UACR, % change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Balcinrenone | -58.0% | 230.3% | −288.4 | 150 mg + 10 mg · wk 12 · n 25 | NCT04595370 Phase 2, primary |
| Canagliflozin | 0.6% | 1.2% | −0.6 | 100mg · wk 104 · n 124 | NCT03436693 Phase 3, secondary |
| Dapagliflozin | -22.4% | -1.8% | −20.6 | 10 mg · wk 24 · n 140 | NCT02547935 Phase 2/3, primary |
| Empagliflozin | -39.1% | -2.6% | −36.5 | 10 mg · wk 14 · n 61 | NCT05182840 Phase 2, primary |
| Sotagliflozin (Inpefa) | -48.1% | -18.7% | −29.4 | 400 mg · wk 26 · n 264 | NCT03242252 Phase 3, secondary |
| Vicadrostat | -38.5% | -6.4% | −32.1 | 20 mg · wk 14 · n 121 | NCT05182840 Phase 2, primary |
Drugs checked with no result here: 32 not reported, 19 trial running, 19 not posted.
eGFR slope
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Roxadustat | -2.6 | -3.2 | +0.6 | n 389 | NCT01887600 Phase 3, secondary |
| Tolvaptan | -2.3 | -3.6 | +1.3 | wk 61 · n 668 | NCT02160145 Phase 3, primary |
Drugs checked with no result here: 32 not reported, 21 trial running, 21 not posted.
Haemoglobin, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Desidustat | 1.9a | 1.8 (darbepoetin) | — | — | NCT04012957 Phase 3, primary |
| Ferric derisomaltose | 1.2 | 1.1 (Iron Sucrose) | — | wk 8 · n 1027 | NCT02940860 Phase 3, primary |
| Pegmolesatide (HS-20039) | 0.1a | -0.2 (epoetin alfa) | — | — | NCT03902691 Phase 3, primary |
| Roxadustat | 2 | 0.2 | +1.8 | wk 52 · n 616 | NCT01750190 Phase 3, primary |
| Vadadustat | 1.4 | 1.4 (Darbepoetin Alfa) | — | n 879 | NCT02648347 Phase 3, primary |
Drugs checked with no result here: 33 not reported, 21 trial running, 17 not posted.
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 76 approved or late-stage drugs with a featured trial in Chronic Kidney Disease were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.